Said a leading authority on pulmonary hypertension.

This product is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension scleroderma occurring forms of the disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy. Specialty pharmaceuticals specialty pharmaceuticals patients with pulmonary hypertension patients with pulmonary hypertension Teva today announced the introduction of epoprostenol is important in reducing the overall financial burden of treating this life-threatening disease, said a leading authority on pulmonary hypertension, Richard Chan Nick, Professor of Medicine at the University of California, San Diego Medical Center.

Food and Drug Administration approval for the Company’s Abbreviated New Drug Application for his epoprostenol market granted, the first generic version of GlaxoSmithKline Flola for Injection. Teva’s approval is for the 0.5 mg base / vial and 1.5 mg base / vial strengths as well as the sterile diluent. The brand product an annual turnover an annual turnover of approximately 80 million dollars in the United States for the 12 months to February 2008, at the IMS sales data..Because the pregnancy causes a variety of changes in body, above all declined lung capacity, coupled with increased cardiac output and consumption of oxygen it brings pregnant woman high risk of complications. In addition, parts of the parent are suppressed the immune system, a process offers essential protection to the fetus of, but takes of the native ‘s ability infections infections.

Researchers point out, though trial after study has does not relationship to the vaccine stabilizing thimerosal and autism found Addition thiomersal – free injectable versions of flu vaccines is available for those who are is continuing concerns.

Both comments and pings are currently closed.

Comments are closed.

Powered by WordPress | Designed by: | Thanks to